Does CLNN pay dividends?

Clene Inc. (CLNN) does not currently pay a regular dividend.

What is CLNN's market cap?

Clene Inc. (CLNN) has a market capitalization of $54.35M with a current stock price of $4.28.

Clene Inc. (CLNN)

Official site

CONSUMER DEFENSIVE • PACKAGED FOODS • NASDAQ

$4.28

+0.05 (+1.18%)

Market Cap: $54.35M

Last updated: Sep 01, 2026 at 10:00 AM ET

Earnings

Performance (10Y)

Beat Rate

39%(9/23)

Avg Surprise

-14.43%

Upcoming Estimates

Sep 30, 2026

EPS Consensus$-0.47

Range$-0.49 - $-0.46

2 analysts

EPS RevisionsNo revisions (7d)No revisions (30d)

EPS Estimate Drift

90d ago$-0.28+41.1%

60d ago$-0.28+41.1%

30d ago$-0.28+41.1%

7d ago$-0.28+41.1%

Current$-0.47

Revenue Consensus

$59200

Range$0 - $130000

5 analysts

Dec 31, 2026

EPS Consensus$-1.18

Range$-1.34 - $-1.02

2 analysts

Revenue Consensus

$107570

Range$-36830 - $258170

5 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$-1.18	$-1.34 - $-1.02	-	-	2	-	-
Sep 30, 2026Sep 26EST	-	$-0.47	$-0.49 - $-0.46	-	-	2	No revisions (30d)	-
Jun 30, 2026Jun 26	$-0.60	$-0.37	$-0.41 - $-0.33	-62.16%	Miss	2	No revisions (30d)	+31.8%
Mar 31, 2026Mar 26	$-0.24	N/A	-	+65.71%	Beat	2	0 1 30d	+52.0%
Dec 31, 2025Dec 25	$-0.78	$-0.42	$-0.58 - $-0.26	-85.38%	Miss	2	1 1 30d	+42.9%
Sep 30, 2025Sep 25	$-0.61	$-0.56	$-0.69 - $-0.36	-8.93%	Miss	3	1 0 30d	+45.0%
Jun 30, 2025Jun 25	$-0.88	$-0.46	$-0.64 - $-0.28	-91.30%	Miss	2	0 1 30d	+32.3%
Mar 31, 2025Mar 25	$-0.50	$-0.78	$-0.99 - $-0.49	+35.90%	Beat	5	1 0 30d	+67.3%
Dec 31, 2024Dec 24	$-1.36	$-0.88	$-1.11 - $-0.42	-55.42%	Miss	5	1 2 30d	-2174.3%
Sep 30, 2024Sep 24	$-1.11	$-1.29	$-1.51 - $-1.09	+13.95%	Beat	5	No revisions (30d)	+27.9%
Jun 30, 2024Jun 24	$-1.30	$-1.42	$-1.60 - $-1.25	+8.45%	Beat	5	No revisions (30d)	+78.5%
Mar 31, 2024Mar 24	$-1.53	$-1.47	$-1.48 - $-1.45	-4.08%	Miss	5	No revisions (30d)	-920.0%
Dec 31, 2023Dec 23	$-0.06	$-0.07	$-0.08 - $-0.06	+14.29%	Beat	4	No revisions (30d)	+98.1%
Sep 30, 2023Sep 23	$-1.54	$-1.53	$-1.56 - $-1.51	-0.65%	Miss	6	No revisions (30d)	+47.6%
Jun 30, 2023Jun 23	$-6.06	$-2.13	$-2.15 - $-2.08	-184.51%	Miss	7	No revisions (30d)	-37.7%
Mar 31, 2023Mar 23	$-0.15	$-0.14	$-0.19 - $-0.11	-7.14%	Miss	6	No revisions (30d)	+96.6%
Dec 31, 2022Dec 22	$-3.15	$-2.48	$-2.53 - $-2.44	-27.02%	Miss	7	No revisions (30d)	-4600.0%
Sep 30, 2022Sep 22	$-2.94	$-4.00	$-4.08 - $-3.97	+26.50%	Beat	7	No revisions (30d)	+8.4%
Jun 30, 2022Jun 22	$-4.40	$-3.70	$-3.72 - $-3.68	-18.92%	Miss	7	No revisions (30d)	-2.3%
Mar 31, 2022Mar 22	$-4.36	$-3.80	$-3.85 - $-3.78	-14.74%	Miss	6	No revisions (30d)	-11.2%
Dec 31, 2021Dec 21	$0.07	N/A	-	+141.18%	Beat	5	1 0 30d	+600.0%
Sep 30, 2021Sep 21	$-3.21	$-3.30	$-3.33 - $-3.22	+2.73%	Beat	5	No revisions (30d)	-4485.7%
Jun 30, 2021Jun 21	$-4.30	$-2.20	$-2.25 - $-2.15	-95.45%	Miss	4	No revisions (30d)	-4200.0%
Mar 31, 2021Mar 21	$-3.92	$-2.00	$-2.01 - $-1.99	-96.00%	Miss	2	No revisions (30d)	-5500.0%
Dec 31, 2020Dec 20	$0.01	N/A	-	+111.11%	Beat	2	No revisions (30d)	+112.5%
Sep 30, 2020Sep 20	$-0.07	N/A	-	N/A	Beat	-	-	-40.0%
Jun 30, 2020Jun 20	$-0.10	N/A	-	N/A	Beat	-	-	-174.7%
Mar 31, 2020Mar 20	$-0.07	N/A	-	N/A	Beat	-	-	-137.3%
Dec 31, 2019Dec 19	$-0.08	N/A	-	N/A	Beat	-	-	-171.2%
Sep 30, 2019Sep 19	$-0.05	N/A	-	N/A	Beat	-	-	+94.5%
Jun 30, 2019Jun 19	$-0.04	N/A	-	N/A	Beat	-	-	-
Mar 31, 2019Mar 19	$-0.03	N/A	-	N/A	Beat	-	-	-
Dec 31, 2018Dec 18	$-0.03	N/A	-	N/A	Beat	-	-	-
Sep 30, 2018Sep 18	$-0.90	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	-1.92	EV/EBITDA	-1.13x
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-5941.00%
ROE	-1738.00%	ROIC	98.14%
Financial Health
Debt/Equity	-0.05x	Interest Coverage	-10.15x
Current Ratio	3.07x	Quick Ratio	3.07x
Trading Statistics
Beta	0.97	Avg Volume	79.20K
52-Week High	$13.50	52-Week Low	$3.88

Technical Indicators Dashboard

Moving Averages

SMA 10$4.35

SMA 20$4.54

SMA 50$5.29

SMA 200$5.88

EMA 10$4.39

EMA 20$4.57

EMA 50$5.08

EMA 200$5.64

MACD

Line: -0.27Signal: -0.32Hist: 0.04

ADX

ADX: 27.3+DI: 13.4-DI: 20.7

Aroon & PSAR

Aroon Up36.0

Aroon Down48.0

PSAR$4.87

Bollinger Bands

Upper Band$5.47

Lower Band$3.62

%B Position4077%(Upper)

Band Width0.36

RSI (14-Day)

Neutral

38.9

Momentum Oscillators

Stoch %K33.0

Stoch %D34.8

Williams %R-61.6

ROC (10d)1.9%

Momentum0.08

CCI (20d)-59.5

MFI (14d)49.9

Volatility Measures

ATR (14d)$0.38(8.8%)

StdDev (20d)0.46

Hist Vol72.8%(High)

Volume Flow

VWAP$4.24

OBV16.4M

AD Line6.5M

CMF (20d)-0.126

Volume Metrics

Avg Vol (20d)81.8K

Vol Ratio0.5x

VWMA (20d)$4.56

Pivot Points

R3$5.16

R2$4.95

R1$4.59

Pivot Point$4.38

S1$4.02

S2$3.81

S3$3.45

Advanced Oscillators

TSI-24.70

Ultimate Osc47.5

KST-207.41

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$90,000	$15,000	$77,000	$15,000	$27,000	$81,000	$91,000	$87,000	$91,000	$73,000	$170,000	$108,000
Cost of Revenue	$36,000	$355,000	$23,000	$0	$366,000	$20,000	$18,000	$18,000	$18,000	$16,000	$460,000	$12,000
Gross Profit	$54,000	$-340,000	$54,000	$15,000	$27,000	$61,000	$73,000	$69,000	$73,000	$57,000	$-290,000	$96,000

Operating Expenses	$5.40M	$1.72M	$7.30M	$5.66M	$5.89M	$4.14M	$8.73M	$7.88M	$7.46M	$9.29M	$9.64M	$9.64M
R&D	$3.47M	$329,000	$5.50M	$3.51M	$3.51M	$1.48M	$5.57M	$4.47M	$4.15M	$5.87M	$6.32M	$5.97M
SG&A	$1.93M	$1.75M	$1.81M	$2.15M	$2.19M	$2.66M	$2.70M	$3.41M	$3.23M	$3.10M	$3.28M	$3.18M
Operating Income	$-5,347,000	$-2,061,000	$-7,244,000	$-5,648,000	$-5,864,000	$-4,076,000	$-8,655,000	$-7,815,000	$-7,391,000	$-9,232,000	$-9,930,000	$-9,542,000

Interest Income	$0	$47,000	$40,000	$40,000	$62,000	$81,000	$110,000	$127,000	$269,000	$359,000	$458,000	$546,000
Interest Expense	$695,000	$791,000	$746,000	$649,000	$679,000	$608,000	$516,000	$1.02M	$1.28M	$1.24M	$1.20M	$1.19M
Income Before Tax	$-13,424,000	$-8,090,999	$-9,226,000	$-8,777,000	$-7,419,000	$-751,000	$-13,549,000	$-7,986,000	$-6,785,000	$-11,080,000	$-10,173,000	$-2,418,000
Income Tax Expense	$0	$0	$0	$0	$0	$0	$0	$0	$-1	$376,724	$12.09M	$-439,000

Net Income	$-13,424,000	$-8,090,999	$-9,226,000	$-8,777,000	$-7,419,000	$-751,000	$-13,549,000	$-7,986,000	$-6,785,000	$-11,080,000	$-10,173,000	$-2,418,000

EBITDA	$-4,994,000	$-6,944,999	$-8,120,000	$-7,763,000	$-6,374,000	$261,000	$-12,628,000	$-6,558,000	$-5,089,000	$-9,416,000	$-8,551,000	$-791,000
EBIT	$-5,347,000	$-7,299,999	$-8,480,000	$-8,128,000	$-6,740,000	$-143,000	$-13,033,000	$-6,964,000	$-5,503,000	$-9,836,000	$-8,973,000	$-1,230,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about CLNN

News

Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses

Clene is set to submit a New Drug Application (NDA) for its ALS drug, CNM-Au8, in Q4, following FDA-requested analyses linking neurofilament light-chain changes to clinical benefits. The company's data indicates a 74% lower 12-month mortality risk in patients with declining or stabilized neurofilament levels, along with improved functional scores and breathing capacity. The FDA may grant accelerated approval, with a potential commercialization decision by early summer 2027.

Yahoo Finance•Aug 19, 2026 9:41 PM8/19/26•

Bullish

Clene to Present at the Emerging Growth Conference

Clene Inc. (Nasdaq: CLNN) announced that its management will present a corporate update at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. The presentation will be available via webcast on the "Events" section of Clene's website. Clene is a late clinical-stage biopharmaceutical company focused on neurodegenerative diseases, developing CNM-Au8® to improve mitochondrial health and neuronal function.

Investing News Network•Aug 18, 2026 1:10 PM8/18/26•

Somewhat-Bullish

Clene to Present at the Emerging Growth Conference

Clene Inc. announced that its management will present a corporate update at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. A webcast of the presentation will be available on Clene's website and through the conference portal, with a replay accessible afterward on the Emerging Growth YouTube Channel. Clene, a late clinical-stage biopharmaceutical company, focuses on treating neurodegenerative diseases by improving mitochondrial health and neuronal function.

www.marketscreener.com•Aug 17, 2026 12:41 PM8/17/26•

Bullish

Clene stock holds at buy as H.C. Wainwright keeps $31 target

H.C. Wainwright has reiterated a Buy rating and a $31 price target for Clene Inc. (NASDAQ:CLNN) after the company received final formal Type C meeting minutes from the FDA, confirming that data could support an accelerated approval pathway for ALS. Clene plans to submit a New Drug Application in Q4 2026 and initiate a confirmatory Phase 3 trial in Q2 2027, despite reporting a wider-than-expected loss per share in Q2 2026 and a significant cash burn.

Investing.com•Aug 17, 2026 12:41 PM8/17/26•

Somewhat-Bullish

Clene schedules a 3:10 p.m. webcast—what will it cover?

Clene (Nasdaq: CLNN) announced its management will deliver a virtual corporate update at the Emerging Growth Conference on August 19, 2026, at 3:10 p.m. ET. The presentation will be webcast and a replay will be available afterward. Clene is a biopharmaceutical company developing CNM-Au8, an investigational therapy for neurodegenerative diseases like ALS, Parkinson’s, and multiple sclerosis, focusing on improving mitochondrial health and neuronal function.

Stock Titan•Aug 17, 2026 12:41 PM8/17/26•

Neutral

Frequently Asked Questions About CLNN

Does CLNN pay dividends?: Clene Inc. (CLNN) does not currently pay a regular dividend.
What is CLNN's market cap?: Clene Inc. (CLNN) has a market capitalization of $54.35M with a current stock price of $4.28.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In